News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kissei Pharmaceutical Co., Ltd. and Eisai Company, Ltd. (ESALY.PK) Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries


6/13/2007 1:14:56 PM

Tokyo, June 12, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created and developed by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in a total of 10 ASEAN countries from Kissei.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES